Search

Displaying results 3391 - 3400 of 5900 in total
  1. Drug

    Sulbutiamine

    go.drugbank.com/drugs/DB13416
    Investigational

    Sulbutiamine is a synthetic derivative of thiamine (vitamin B1) under the market name Arcalion that is composed of two modified thiamine molecules to form a dimer. … Although its clinical efficacy is not yet defined, sulbutiamine is used to treat asthenia.

  2. Drug

    Acetylcholine

    go.drugbank.com/drugs/DB03128
    ApprovedInvestigational

    A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central ner...

    Synonyms: O-Acetylcholine
  3. Drug

    Cefotetan

    go.drugbank.com/drugs/DB01330
    ApprovedInvestigational

    The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.

  4. Drug

    SR-9011

    go.drugbank.com/drugs/DB14014
    Experimental

    SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues

  5. Drug

    4-(Isopropylamino)diphenylamine

    go.drugbank.com/drugs/DB14195
    Approved

    Sensitivity to this compound may be identified with a clinical patch test.

  6. Drug

    G207

    go.drugbank.com/drugs/DB05827
    Investigational

    G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG. … MediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable as a therapeutic agent in humans.

  7. Drug

    SR-9009

    go.drugbank.com/drugs/DB14013
    Experimental

    SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues

  8. Drug

    2,2'-Dibenzothiazyl disulfide

    go.drugbank.com/drugs/DB14201
    Approved

    Sensitivity to 2,2'-Dibenzothiazyl disulfide may be identified with a clinical patch test.

  9. Drug

    Asundexian

    go.drugbank.com/drugs/DB19088
    Investigational

    Transient Ischemic Attack, a So-called Mini Stroke). … Asundexian is under investigation in clinical trial NCT05686070 (A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk

  10. Drug

    Cyclopentamine

    go.drugbank.com/drugs/DB08999
    ApprovedWithdrawn

    It has been widely discontinued due to the safety, effectiveness, and availability of a similar drug, propylhexedrine.